What We're Reading
Industry reads hand-picked by our editors
Jan 18, 2019
Jan 17, 2019
Jan 16, 2019
Jan 15, 2019
-
Why Novo Nordisk should buy Amarin
Vantage
-
Amid Onpattro launch, Alnylam raises $387.5M
BioCentury
-
In Fast-Aging Japan, Elder Care Is a High-Tech Pursuit
The Wall Street Journal
-
Walmart Expected to Leave CVS Caremark Pharmacy Networks Amid Dispute
The Wall Street Journal
Jan 14, 2019
-
Lilly eyes more cancer deals, but wary of CAR-T, gene therapy
Reuters
-
Samsung Faces Resistance From Big Pharma in the U.S.
The Wall Street Journal
-
The Game Isn't Worth The Candle: Reflections on the JPM Healthcare Conference
Life Sci VC
-
What happened when biotech startup pursued a new treatment for pancreatic cancer.
The Washington Post
Jan 11, 2019
-
Ex-Banker Walks Into a Conference, Walks Out With $480 Million
Bloomberg
-
'Marketers are having a field day': Patients stuck in corporate fight against generic drugs
The Washington Post
-
Patent reform back on agenda in China
BioCentury
-
Her insurer's price tool estimated less than $1,375 for a breast MRI. Then she got a bill for $3,200.
The Inquirer